Bavarian Nordic AS

BAVA

Equity

ISIN DK0015998017 / Valor 944279

Nasdaq Copenhagen Equities (2026-06-04)

DKK 182.60+1.78%

Bavarian Nordic AS
UMushroom community rating:

5.00 1 votes No rating yet

NegativeNeutralPositive

About company

Bavarian Nordic is a Denmark-based biotechnology company that researches, develops, manufactures and commercializes vaccines and cancer immunotherapies built principally on its Modified Vaccinia Ankara (MVA‑BN) platform. Its best-known product is the non‑replicating smallpox/monkeypox vaccine marketed as JYNNEOS/Imvanex/Imvamune, which has driven much of the company’s commercial activity and supply agreements with governments for biodefense stockpiles. In addition to government and public‑health contracts, Bavarian Nordic maintains in‑house GMP manufacturing capacity that supports commercial supply and contract manufacturing, and it is advancing a pipeline that includes infectious‑disease vaccines and oncology immunotherapy candidates. The company is publicly listed in Denmark and positions itself at the intersection of commercial vaccine sales, government procurement and ongoing clinical development.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

1.22%1Y

-5.80%3Y

-34.7%5Y

Performance

38.4%1Y

47.3%3Y

54.3%5Y

Volatility